BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company’s phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matched to treat specific patients. It develops BX011, a fixed multi-phage cocktail, which is in Phase 2a trial for the treatment of diabetic foot infections; and BX211, a phage therapy, which is in Phase 2 trial for the treatment of diabetic foot osteomyelitis. BiomX Inc. was founded in 2015 and is based in Dover, Delaware.
Metrics to compare | PHGE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHGEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.3x | −3.8x | −0.5x | |
PEG Ratio | 0.00 | −0.02 | 0.00 | |
Price/Book | −0.5x | 3.6x | 2.6x | |
Price / LTM Sales | - | 13.6x | 3.2x | |
Upside (Analyst Target) | - | 925.9% | 51.2% | |
Fair Value Upside | Unlock | 1.4% | 7.3% | Unlock |